Market closedNon-fractional

Ikena Oncology/IKNA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Ikena Oncology

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Ticker

IKNA

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Boston, United States

Employees

34

Ikena Oncology Metrics

BasicAdvanced
$80M
Market cap
-
P/E ratio
-$1.57
EPS
0.34
Beta
-
Dividend rate
$80M
0.34
15.849
15.473
4.057
6.273
-29.04%
-48.28%
19.304
0.52
0.52
-0.946
-78.08%
-14.17%
-25.86%
-53.26%

What the Analysts think about Ikena Oncology

Analyst Ratings

Majority rating from 5 analysts.
Buy

Ikena Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$16M
-17.01%
Profit margin
0.00%
-100.00%

Ikena Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.44
-$0.40
-$0.47
-$0.33
-
Expected
-$0.47
-$0.43
-$0.43
-$0.41
-$0.35
Surprise
-7.25%
-6.98%
9.81%
-20.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ikena Oncology stock?

Ikena Oncology (IKNA) has a market cap of $80M as of July 06, 2024.

What is the P/E ratio for Ikena Oncology stock?

The price to earnings (P/E) ratio for Ikena Oncology (IKNA) stock is 0 as of July 06, 2024.

Does Ikena Oncology stock pay dividends?

No, Ikena Oncology (IKNA) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Ikena Oncology dividend payment date?

Ikena Oncology (IKNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Ikena Oncology?

Ikena Oncology (IKNA) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Ikena Oncology stock

Buy or sell Ikena Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing